Malaria infection and morbidity in infants in relation to genetic polymorphisms in Tanzania.
To investigate the effects of host polymorphisms on malaria morbidity and infection, the frequency distributions of TNF alpha promotor gene and sickle cell trait were studied in infants in an area highly endemic for Plasmodium falciparum transmission in Tanzania. Differences in parasite prevalence, density, febrile episodes with and without parasitaemia, PCV levels and the frequencies of different MSP-2 parasite infections were assessed by genotype. The frequency of the TNF alpha promotor allele 2 was 0.09, and the trait was in Hardy-Weinberg equilibrium. There were no differences in malariametric indices between infants with the normal TNF alpha promoter gene and those who were heterozygous for this trait. Infants heterozygous for the TNF alpha promotor gene appeared to have fewer febrile episodes when they were free of parasites. The two infants homozygous for the TNF alpha promoter allele 2 had both a much higher incidence of fever, independently of parasitaemia, than the average for the other genotypes. The frequency of the sickle cell allele S was 0.06 and the trait was also in Hardy-Weinberg equilibrium. Infants heterozygous for the sickle cell trait had significantly lower parasite densities, but similar prevalence, and MSP-2 infections compared to infants with normal haemoglobin. PCV levels, and the incidence of febrile episodes both with and without parasitaemia were also similar. In contrast to the sickle cell trait, the TNF alpha promotor polymorphism appeared not to have any protective effect on malaria in this study, and its importance in other unspecified fever-causing diseases in this population needs further investigation.
Stirnadel
H A
HA
Swiss Tropical Institute, Basel. stirnadel@ubaclu.unibas.ch
Stöckle
M
M
Felger
I
I
Smith
T
T
Tanner
M
M
Beck
H P
HP
D000483:Alleles; D000818:Animals; D000953:Antigens, Protozoan; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000453:epidemiology / Q000235:genetics* / Q000469:parasitology; D010963:Plasmodium falciparum / Q000302:isolation & purification; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D015800:Protozoan Proteins / Q000302:isolation & purification; D012805:Sickle Cell Trait / Q000235:genetics; D013636:Tanzania / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
D000953:Antigens, Protozoan; D015800:Protozoan Proteins; D014409:Tumor Necrosis Factor-alpha; C065974:merozoite surface protein 2, Plasmodium